Imagery as Biomarker of Gout

Status Recruiting

Clinical Trial Summary

The objective of this study is to determine whether MSU crystal deposits visualized on ultrasound and/or DECT are associated with the development of symptomatic gout (according to ACR 2015 / EULAR criteria) over 5 years in hyperuricemic individuals.

Clinical Trial Description

Cross-sectional studies have shown that 17% to 86% of people with apparently asymptomatic hyperuricemia have ultrasound evidence of monosodium urate (MSU) crystal deposition. These observations suggest that this deposition constitutes the first stage of the clinical gout syndrome, which has led to a revised model of disease progression and staging. However, no longitudinal studies have been undertaken to determine whether such findings are needed for the development of gout, or to investigate pathological mechanisms responsible for the transition from asymptomatic crystalline deposit to gout. Only a prospective cohort study of people at risk who are carefully and regularly followed can answer such questions. Dual-energy computed tomography (DECT) and ultrasound are the two imaging techniques that allow the visualization and quantification of MSU crystals. Ultrasound is the most widely used technique; it allows the identification of the deposit of crystals of on the surface of the cartilage (double contour sign) and of the tophi. The DECT can detect the deposition of MSU crystals in soft tissues as long as the amount of crystals exceeds the spatial resolution of the machine (about 250 μm). The international collaborative study TIGER (Transitions in gout research study) aims to address the question of the predictive value of the deposition of MSU crystals "silent" in the development of gout, through an international cohort (7 countries) including 907 asymptomatic hyperuricaemic individuals. These individuals will have initial ultrasounds to investigate the presence of MSU crystal deposits and a 5-year follow-up. Given the aforementioned ultrasound reproducibility issues, DECT analyzes will be added to the baseline assessment of TIGER participants to provide exploratory data on DECT as a potential biomarker for the impending development of gout. ;

Study Design

Related Conditions & MeSH terms

Hyperuricemia

Clinical Trial Details

NCT number	NCT05434858
Study type	Interventional
Source	Lille Catholic University
Contact	Marie Desolere
Phone	+33320225931
Email	desolere.marie@ghicl.net
Status	Recruiting
Phase	N/A
Start date	September 9, 2022
Completion date	September 9, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04060173` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671	Phase 1
Recruiting	`NCT05504083` - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients	Phase 2
Completed	`NCT04966325` - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects	Early Phase 1
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT00995618` - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia	Phase 2
Completed	`NCT00288158` - Primary Prevention of Hypertension in Obese Adolescents	Phase 2
Terminated	`NCT04987294` - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease	Phase 2
Completed	`NCT04236219` - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers	Phase 1
Completed	`NCT06189404` - Effect of Tigulixostat on the Pharmacokinetics of Theophylline	Phase 1
Recruiting	`NCT05586958` - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients	Phase 3
Recruiting	`NCT06084585` - The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia	N/A
Recruiting	`NCT06056570` - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia	Phase 1/Phase 2
Not yet recruiting	`NCT04586803` - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers	Phase 1
Completed	`NCT02959918` - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid	Phase 2
Not yet recruiting	`NCT02944214` - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients	N/A
Completed	`NCT02557126` - Study of URC102 to Assess the Safety and Efficacy in Gout Patients	Phase 2
Active, not recruiting	`NCT01021241` - Safety and Efficacy Study of Intravenous Uricase-PEG 20	Phase 1
Completed	`NCT00756964` - Lowering Serum Uric Acid to Prevent Acute Kidney Injury	Phase 2
Terminated	`NCT00607152` - Rasburicase (Fasturtec) Registration Trial	Phase 3
Completed	`NCT03906006` - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Imagery as Biomarker of Gout — TIGER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms